Vergoeding 2019-2023 voor ATC-subgroep A10BH : Dipeptidylpeptidase-4-remmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| A10BH01 Sitagliptine (Januvia ®) | 9.659.400 | 10.550.800 | 10.431.900 | 10.661.700 | 7.797.700 |
| A10BH02 Vildagliptine (Galvus ®) | 1.457.200 | 1.431.100 | 1.229.900 | 1.121.600 | 1.052.700 |
| A10BH03 Saxagliptine (Onglyza ®) | 391.220 | 350.170 | 298.160 | 270.100 | 231.990 |
| A10BH05 Linagliptine (Trajenta ®) | 2.905.300 | 3.282.900 | 3.248.800 | 3.429.100 | 3.162.000 |
| Totaal | 14.413.120 | 15.614.970 | 15.208.760 | 15.482.500 | 12.244.390 |